A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

IntegriChain, the leading provider of revenue optimization technology and insights for the pharmaceutical industry, today announced the hiring of Clay Willis. Willis brings IntegriChain more than a ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie ...

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

AbbVie Inc. and other drug makers lost a bid to block a Tennessee law regulating contracts between pharmaceutical companies ...

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration by finding that drug manufacturers must obtain pre-approval from HRSA before implementing ...

Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...